Pharmacokinetics of Calcium Antagonists Under Development

Clinical Pharmacokinetics

Volumn 15, Issue 1, 1988, Pages 1-14

  Abernethy, Darrell R ^a,b   Schwartz, Janice B ^a,b  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CIMETIDINE; DIGOXIN; FELODIPINE; ISRADIPINE; NICARDIPINE; NILVADIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; TIAPAMIL;

AGED; CLINICAL ARTICLE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; NORMAL VALUE; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW;

ADULT; AGED; AGED, 80 AND OVER; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIHYDROPYRIDINES; DRUG EVALUATION; DRUG INTERACTIONS; HUMAN; KIDNEY DISEASES; LIVER DISEASES; PROPYLAMINES;

EID: 0023788089     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-198815010-00001     Document Type: Review

References (67)

1. Steady-state pharmacokinetics of nisoldipine after i.v. infusion in healthy volunteers
2. The current status of the mechanism of the calcium channel antagonists
3. Bias in pharmacokinetics and clinical pharmacology
4. Pharmacokinetics of nitrendipine in patients with renal failure: comparison to normal subjects
5. Long-acting dihydropyridine calcium antagonists I: 2-alkoxymethyl derivatives incorporating basic substituents
6. Noncompartmental determination of steady-state volume of distribution
7. Pharmacokinetics and haemodynamic effects of nisoldipine in patients with liver cirrhosis
8. Safety, efficacy and pharmacokinetics of nicardipine in elderly hypertensive patients
9. Hypotensive effect and pharmacokinetics of nicardipine in patients with severe renal failure
10. A review of the human metabolism and pharmacokinetics of nicardipine hydrochloride
11. Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview
12. The effect of dextro, levo, and racemic verapamil on atrioventricular conduction in man
13. Clinical pharmacokinetics of verapamil, nifedipine, and diltiazem
14. Effects of d, 1-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism
15. Absorption, distribution, and elimination of felodipine in man
16. Felodipine kinetics in healthy men
17. Pharmacokinetics of (+), (−), and (±)-verapamil after intravenous administration
18. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily
19. History of calcium antagonists
20. Effect of nicardipine in elderly hypertensive patients
21. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects
22. Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls
23. Stereo-selective pharmacodynamics of verapamil
24. Nitrendipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension
25. Pharmacokinetics of nicardipine following oral and intravenous administration in man
26. The metabolism and pharmacokinetics of nicardipine hydrochloride in man
27. Pharmacokinetic studies on nicardipine hydrochloride, a new vasodilator, after repeated administration to rats, dogs and humans
28. Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro
29. Comparative pharmacokinetics and cardiovascular effects of tiapamil in healthy volunteers and patients with hepatic cirrhosis
30. Verapamil competitively inhibits alpha-1 adrenergic and muscarinic but not beta-adrenergic receptors in rat myocardium
31. The influence of age on the pharmacokinetics of nitrendipine
32. Pharmacokinetics of nitrendipine in liver disease
33. Clinical pharmacokinetics of nimodipine in normal and impaired renal function
34. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans
35. Nifedipine: kinetics and dynamics in healthy subjects
36. Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship
37. Beeinflussen nisoldipin, nitrendipin, und nimodipin die pharmakokinetik und wirksamketi von herzglykosiden
38. Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency
39. The effects of nicardipine in hypertensive subjects with impaired renal function
40. Interaction between digoxin and the calcium antagonists nicardipine and tiapamil
41. The heterogeneity of the slow channel blockers (calcium antagonists)
42. Plasma protein binding of nilvadipine, a new dihydropyridine calcium antagonist, in man and dog
43. First-pass elimination: basic concepts and clinical consequences
44. Pharmacokinetics and metabolism of nifedipine
45. Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage
46. Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine
47. The metabolism of nicardipine hydrochloride in healthy male volunteers
48. Effect of chronic vs acute dosing of nitrendipine in chronic liver disease
49. Effects of amlodipine on steady-state digoxin concentrations and renal digoxin clearance
50. An investigation of the cause of accumulation of verapamil during regular dosing of patients
51. Pharmacokinetic, haemodynamic and radionuclide studies with nicardipine in coronary artery disease
52. The mechanism of action of calcium antagonists relative to their clinical applications
53. Calcium antagonist drugs, receptor interactions that clarify therapeutic effects
54. Nicardipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension, and related cardiovascular disorders
55. Pharmaockinetics of nilvadipine in healthy volunteers
56. Effect of two different meals on bioavailability of nilvadipine in healthy volunteers
57. Study of nifedipine photodecomposition in plasma and whole blood using capillary gas-liquid chromatography
58. Plasma protein binding and erythrocyte partitioning of nicardipine in vitro
59. Pharmacokinetics and haemodynamic effects of nisoldipine and its interaction with cimetidine in healthy volunteers
60. Pharmacology of calcium entry blockers: interaction with vascular alpha-adrenoceptors
61. Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid hemorrhage
62. Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique
63. Pharmacokinetics and metabolism of tiapamil
64. A physiological approach to hepatic drug clearance
65. Study of pharmacokinetic and pharmacodynamic interaction between nitrendipine and digoxin